UPSTREAM BIO, INC. Net Income
UPSTREAM BIO, INC. (UPB) reported Net Income of -$39.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- UPSTREAM BIO, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$39.70M.
- UPSTREAM BIO, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$40.59M.
- UPSTREAM BIO, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$42.46M.
- UPSTREAM BIO, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$33.75M.
- UPSTREAM BIO, INC. net income (loss) attributable to parent for fiscal 2025 was -$143.44M.
- UPSTREAM BIO, INC. net income (loss) attributable to parent for fiscal 2024 was -$62.81M.
- UPSTREAM BIO, INC. net income (loss) attributable to parent for fiscal 2023 was -$20.54M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.70M 10-Q · filed 2026-08-11 | -$80.29M 10-Q · filed 2026-08-11 | -$122.75M derived: sum of 3 quarters · filed 2026-08-11 | -$156.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$40.59M 10-Q · filed 2026-08-11 | -$83.05M derived: sum of 2 quarters · filed 2026-08-11 | -$116.80M derived: sum of 3 quarters · filed 2026-08-11 | -$156.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$42.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$76.21M derived: sum of 2 quarters · filed 2026-03-26 | -$116.17M derived: sum of 3 quarters · filed 2026-08-11 | -$143.44M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$33.75M 10-Q · filed 2025-11-05 | -$73.71M derived: sum of 2 quarters · filed 2026-08-11 | -$100.98M 10-Q · filed 2025-11-05 | -$122.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$39.97M 10-Q · filed 2026-08-11 | -$67.24M 10-Q · filed 2026-08-11 | -$88.48M derived: sum of 3 quarters · filed 2026-08-11 | -$104.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$27.27M 10-Q · filed 2026-08-11 | -$48.51M derived: sum of 2 quarters · filed 2026-08-11 | -$64.50M derived: sum of 3 quarters · filed 2026-08-11 | -$79.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$21.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$37.23M derived: sum of 2 quarters · filed 2026-03-26 | -$51.91M derived: sum of 3 quarters · filed 2026-03-26 | -$62.81M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$15.99M 10-Q · filed 2025-11-05 | -$30.67M derived: sum of 2 quarters · filed 2025-11-05 | -$41.56M 10-Q · filed 2025-11-05 | -$53.40M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$14.68M 10-Q · filed 2025-11-05 | -$25.57M 10-Q · filed 2025-08-06 | -$37.41M derived: sum of 3 quarters · filed 2025-11-05 | -$40.51M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-03-31 | -$10.89M 10-Q · filed 2025-11-05 | -$22.73M derived: sum of 2 quarters · filed 2025-11-05 | -$25.83M derived: sum of 3 quarters · filed 2025-11-05 | -$28.37M derived: sum of 4 quarters · filed 2025-11-05 |
| 2023-12-31 | -$11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$14.94M derived: sum of 2 quarters · filed 2025-03-12 | -$17.48M derived: sum of 3 quarters · filed 2025-03-12 | -$20.54M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$3.10M 10-Q · filed 2024-11-07 | -$5.64M derived: sum of 2 quarters · filed 2024-11-07 | -$8.70M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$2.54M 10-Q · filed 2024-11-07 | -$5.60M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | -$3.06M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |